RSS-Feed abonnieren
DOI: 10.1055/s-2007-981270
© Georg Thieme Verlag Stuttgart · New York
Aktueller Stand der Diagnostik und Therapie der Peritonitis
Current Status of Diagnostics and Therapy of Complicated Intraabdominal InfectionsPublikationsverlauf
Publikationsdatum:
01. Oktober 2007 (online)
Zusammenfassung
Das Krankheitsbild der Peritonitis ist trotz verbesserter Diagnostik und Therapiemöglichkeiten eine erhebliche Herausforderung für die Medizin geblieben. Die Prognose der sekundären Peritonitis ist abhängig von der zeitgerechten Diagnostik und Therapie. Standardverfahren in der Bildgebung ist die kontrastmittelverstärkte Computertomografie. Die antimikrobielle Therapie sowie weitere organunterstützende Verfahren beginnen bereits vor der Operation und werden kontrolliert intra- und postoperativ fortgesetzt. Die Chirurgie dient der Ursachenbehebung. Ziel ist ein einzeitiges Vorgehen mit effektiver Ursachen- und Fokussanierung sowie ausgiebiger Lavage des Abdomens zur Vermeidung von Komplikationen und Reduktion der Letalität.
Abstract
Regardless of improved diagnostics and therapeutic options, complicated intraabdominal infections remain a challenge in medicine. The prognosis of secondary peritonitis depends upon diagnosis and therapy in time. Diagnostic gold-standard is the computed tomography enhanced by contrast medium. Antimicrobial and supportive therapy is initiated before surgery and should be continued throughout and after the operation. Surgery aims on clearing the focus with a one-step-procedure in order to reduce perioperative morbidity and mortality.
Schlüsselwörter
Peritonitis - Diagnostik - chirurgische Therapie - cIAI
Key words
peritonitis - diagnostics - surgical treatment - cIAI
Literatur
- 1 Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez A L, Beale R, Svoboda P, Laterre P F, Simon S. et al . Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003; 290 238-247
- 2 Barie P S, Williams M D, McCollam J S, Bates B M, Qualy R L, Lowry S F, Fry D E. Benefit / risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg. 2004; 188 212-220
- 3 Berger D, Buttenschoen K. Management of abdominal sepsis. Langenbecks Arch Surg. 1998; 383 35-43
- 4 Bernard G R, Vincent J L, Laterre P F, LaRosa S P, Dhainaut J F, Lopez-Rodriguez A, Steingrub J S, Garber G E, Helterbrand J D, Ely E W. et al . Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344 699-709
- 5 Bochud P Y, Glauser M P, Calandra T. Antibiotics in sepsis. Intensive Care Med. 2001; 27 Suppl 1 33-48
- 6 Bodmann K F, Graninger W. Sepsis. Chemother J. 2004; 13 89-93
- 7 Bodmann K F, Vogel F. Antimikrobielle Therapie der Sepsis. Chemotherapie Journal. 2001; 1 43-56
- 8 Bosscha K, van Vroonhoven T J, van der Werken C. Surgical management of severe secondary peritonitis. Br J Surg. 1999; 86 1371-1377
- 9 Büchler M W, Baer H U, Brugger L E, Feodorovici M A, Uhl W, Seiler C. Chirurgische Therapie der diffusen Peritonitis: Herdsanierung und intraoperative extensive Lavage. Chirurg. 1997; 68 811-815
- 10 Dollinger P, Harnoss B M, Berger G, Häring R. Die postoperative Peritonitis. In: Peritonitis. Häring R (ed). Thieme, Stuttgart, New York 1993; 91-96
- 11 Elebute E A, Stoner H B. The grading of sepsis. Br J Surg. 1983; 70 29-31
- 12 Farthmann E H, Schoffel U. Principles and limitations of operative management of intraabdominal infections. World J Surg. 1990; 14 210-217
- 13 Gajic O, Urrutia L E, Sewani H, Schroeder D R, Cullinane D C, Peters S G. Acute abdomen in the medical intensive care unit. Crit Care Med. 2002; 30 1187-1190
- 14 Garcia-Tsao G. Spontaneous bacterial peritonitis. Gastroenterol Clin North Am. 1992; 21 257-275
- 15 Jacobson L E, Gomez G A, Broadie T A. Primary repair of 58 consecutive penetrating injuries of the colon: should colostomy be abandoned?. Am Surg. 1997; 63 170-177
- 16 Johnson C C, Baldessarre J, Levison M E. Peritonitis: update on pathophysiology, clinical manifestations, and management. Clin Infect Dis. 1997; 24 1035-1045
- 17 Keane W F, Alexander S R, Bailie G R, Boeschoten E, Gokal R, Golper T A, Holmes C J, Huang C C, Kawaguchi Y, Piraino B. et al . Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update. Perit Dial Int. 1996; 16 557-573
- 18 Knaus W A, Draper E A, Wagner D P, Zimmerman J E. APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13 818-829
- 19 Lamme B, Boermeester M A, Reitsma J B, Mahler C W, Obertop H, Gouma D J. Meta-analysis of relaparotomy for secondary peritonitis. Br J Surg. 2002; 89 1516-1524
- 20 Levy E, Palmer D L, Frileux P, Hannoun L, Nordlinger B, Tiret E, Honiger J, Parc R. Septic necrosis of the midline wound in postoperative peritonitis. Successful management by debridement, myocutaneous advancement, and primary skin closure. Ann Surg. 1988; 207 470-479
- 21 Linder M M, Wacha H, Feldmann U, Wesch G, Streifensand R A, Gundlach E. [The Mannheim peritonitis index. An instrument for the intraoperative prognosis of peritonitis]. Chirurg. 1987; 58 84-92
- 22 Marshall J C, Innes M. Intensive care unit management of intra-abdominal infection. Crit Care Med. 2003; 31 2228-2237
- 23 Mikulicz J. Weitere Erfahrungen über die operative Behandlung der Perforationsperitonitis. Arch Klin Chir (Berl). 1889; 39 756-784
- 24 Ohmann C, Wittmann D H, Wacha H. Prospective evaluation of prognostic scoring systems in peritonitis. Peritonitis Study Group. Eur J Surg. 1993; 159 267-274
- 25 Panacek E A, Marshall J C, Albertson T E, Johnson D H, Johnson S, MacArthur R D, Miller M, Barchuk W T, Fischkoff S, Kaul M. et al . Efficacy and safety of the monolconal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med. 2004; 32 2173-2182
- 26 Peter F W, Haring R, Hirner A, Sobel A. Frühe Relaparotomie bei postoperativer Peritonitis. Zentralbl Chir. 1989; 114 844-850
- 27 Polk Jr H C, Fry D E. Radical peritoneal debridement for established peritonitis. The results of a prospective randomized clinical trial. Ann Surg. 1980; 192 350-355
- 28 Schein M. Surgical management of intra-abdominal infection: is there any evidence?. Langenbecks Arch Surg. 2002; 387 1-7
- 29 Seiler C A, Brugger L, Forssmann U, Baer H U, Buchler M W. Conservative surgical treatment of diffuse peritonitis. Surgery. 2000; 127 178-184
- 30 Skau T, Nystrom P O, Carlsson C. Severity of illness in intra-abdominal infection. A comparison of two indexes. Arch Surg. 1985; 120 152-158
- 31 Solomkin J S, Mazuski J E, Baron E J, Sawyer R G, Nathens A B, DiPiro J T, Buchman T, Dellinger E P, Jernigan J, Gorbach S. et al . Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis. 2003; 37 997-1005
- 32 Teichmann W, Wittmann D H, Andreone P A. Scheduled reoperations (etappenlavage) for diffuse peritonitis. Arch Surg. 1986; 121 147-152
- 33 van Goor H, Hulsebos R G, Bleichrodt R P. Complications of planned relaparotomy in patients with severe general peritonitis. Eur J Surg. 1997; 163 61-66
- 34 Vogel F B, Bodmann K F. Empfehlungen zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen. Chemother J. 2004; 13 46-105
- 35 Vogel F, Elies W, Bodmann K F, Lode H, Scholz H. Respiratorische Infektionen / HNO-Infektionen. Chemother J. 2004; 13 64-73
- 36 Wacha H, Hau T, Dittmer R, Ohmann C. Risk factors associated with intraabdominal infections: a prospective multicenter study. Peritonitis Study Group. Langenbecks Arch Surg. 1999; 384 24-32
- 37 Wacha H, Kujath P, Trautmann M. Intraabdominelle Infektionen. Chemother J. 2004; 13 74-78
- 38 Warren B L, Eid A, Singer P, Pillay S S, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A. et al . Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001; 286 1869-1878
- 39 Wheeler A P, Bernard G R. Treating patients with severe sepsis. N Engl J Med. 1999; 340 207-214
PD Dr. H.-P. Knaebel , MBA
Aesculap AG & Co KG
Am Aesculap-Platz
78532 Tutlingen
Telefon: +49 / 74 61 / 95 16 30
Fax: +49 / 74 61 / 95 20 71
eMail: hanns-peter.knaebel@aesculap.de